Evidence map›Paper›PMID 37941839›Full record

ReviewCardiovascular diagnosis and therapy2023

A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study.

Carlos Escobar, Ramón Bover Freire, Xavier García-Moll Marimón, Carlos González-Juanatey, Miren Morillas, Alfonso Valle Muñoz, Juan José Gómez Doblas

Open access · diamondAbstract readReview
In one paragraph

Review in Cardiovascular diagnosis and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 1 country.

Carlos EscobarCardiology Department, Hospital Universitario La Paz, Madrid, Spain.
Ramón Bover FreireCardiology Department, Hospital Clínico San Carlos, Madrid, Spain.
Xavier García-Moll MarimónCardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Carlos González-JuanateyCardiology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
Miren MorillasCardiology Department, Hospital de Galdakao, Galdakao, Spain.
Alfonso Valle MuñozCardiology Department, Hospital Marina Salud, Denia, Spain.
Juan José Gómez DoblasCardiology Department, Hospital Universitario Virgen de la Victoria, CIBERCV, Málaga, Spain.
Hospital Clínico San Carlos · ESHospital Clínico Universitario Virgen de la Victoria · ESHospital de Galdakao · ESHospital de Sant Pau · ESHospital Marina Baixa · ESHospital Universitario La Paz · ESHospital Universitario Lucus Augusti · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: During the COVID-19 pandemic, guideline documents on the management of anticoagulation were rapidly published. However, these documents did not follow a structured methodology, and significant differences existed between the guidelines. The aim of this expert consensus was to provide recommendations on the clinical management of oral anticoagulation in patients in the context of the COVID-19 pandemic. Methods: A two-round Delphi study was conducted using an online survey. In the first round, panellists expressed their level of agreement with the items on a 9-point Likert scale. Items were selected if they received approval from ≥66.6% of panellists and if they were agreed by the scientific committee. In the second round, panellists revaluated those items that did not meet consensus in the first round. Results: A total of 147 panellists completed the first round, and 144 of them completed the second round. Consensus was reached on 161 items included in five dimensions. These dimensions addressed: (I) management of anticoagulation in patients with atrial fibrillation (AF) without mechanical valves or moderate/severe mitral stenosis during COVID-19 infection; (II) thromboprophylaxis in patients hospitalised for COVID-19; (III) management of anticoagulation at hospital discharge/after COVID-19; (IV) anticoagulation monitoring in the COVID-19 pandemic setting; and (V) role of telemedicine in the management and follow-up of patients with AF in the COVID-19 pandemic setting. Conclusions: These areas of collective agreement could specially guide clinicians in making decisions regarding anticoagulation in patients with COVID-19 during hospitalisation and at discharge, where results from clinical trials are still limited and, in some cases, conflicting.

Indexed as

atrial fibrillation (AF)COVID-19Delphi consensusOral anticoagulation

Identifiers

PMID37941839
PMCPMC10628427
OpenAlexW4388196220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.